Logo
NEXFILL Deep (1ml with Lidocaine)

NEXFILL Deep (1ml with Lidocaine)

Nexfill

Dermal filler
  • CE Marked dermal filler, with CE certification obtained via a European representative in Germany for compliance with medical device standards.
  • Manufactured using EDQM Approved hyaluronic acid raw material and strict quality Control procedures.
  • Tested by accredited laboratories (e.g., Korea Testing & Research Institute) for parameters such as pH, BDDE residuals (0 ppm detected), heavy metals, endotoxins and protein residues, injection force, osmolarity and volume accuracy.
  • Produced under Nexus Pharma’s quality management system consistent with international standards for medical and aesthetic injectable products.
  • Marketing information emphasises ultra Low impurities, BDDE residue below detection limit and endotoxin levels below 0.1 EU/ml, supporting a high safety profile when used as directed.
Monophasic cross-linked hyaluronic acid dermal filler for deep wrinkles and lips

Description

NEXFILL Deep (1ml with Lidocaine) is a CE-marked, Korean monophasic cross-linked hyaluronic acid dermal filler designed for the treatment of moderate-to-deep wrinkles and structural facial areas such as lips, nasolabial folds, marionette lines, glabella, nose and forehead contour. The gel contains 24 mg/ml high-purity hyaluronic acid with 0.3% lidocaine to improve patient comfort and is supplied in a 1 ml pre-filled syringe. Thanks to Nexus Pharma’s High Density Tapping Technology and ultra-low impurity manufacturing, Nexfill Deep delivers deep, natural hydration, strong lifting capacity and long-lasting, natural-looking results while using around 60% less BDDE cross-linking agent than typical industry fillers, resulting in minimal swelling and high purity.

Bnefits

  • Provides deep, natural hydration while restoring lost volume and structure.
  • Rejuvenates the skin, promoting a more youthful and refreshed appearance.
  • Creates a radiant, healthy skin glow through improved hydration and dermal support.
  • Fills and tightens the skin, quickly smoothing moderate-to-deep wrinkles and folds.
  • Adds definition and volume to lips, nose, chin and other structural areas.
  • Monophasic gel with high viscoelasticity for smooth, even extrusion and natural contours.
  • Uses approximately 60% less BDDE than standard fillers, with BDDE residue below detection limit, reducing swelling and impurity-related risks.
  • Contains 0.3% lidocaine to enhance comfort by reducing pain during and immediately after injection.
  • Results typically last around 6–12 months depending on indication, skin type, lifestyle and injection technique.
  • Easily reversible with hyaluronidase if adjustment or dissolution is required.

Indications

  • Deep wrinkles and folds of the mid and lower face.
  • Nasolabial folds (nose-to-mouth lines).
  • Marionette lines (corners of the mouth).
  • Glabellar lines (frown lines), in appropriately selected patients.
  • Lips – volume, contouring and definition.
  • Nose and forehead contouring (non-surgical rhinoplasty-style refinement in trained hands).
  • Chin augmentation and improvement of chin projection and contour.
  • General facial contouring and moderate volume restoration where a medium-depth filler is appropriate.

Composition

  • Cross-linked hyaluronic acid 24 mg/ml (24 mg per 1 ml syringe).
  • Lidocaine 0.3% (approximately 3 mg per 1 ml) for local anaesthesia and improved treatment comfort.
  • BDDE (1,4-butanediol diglycidyl ether) as the cross-linking agent, with approximately 60% lower BDDE usage than typical industry fillers and residual BDDE below the analytical detection limit according to manufacturer testing.
  • Physiological buffer and isotonic excipients in purified water for injection to form a sterile, viscoelastic, monophasic gel.
  • Each box contains one 1 ml pre-filled syringe of Nexfill Deep.

Formulation

  • Premium monophasic, homogenous hyaluronic acid gel with high viscoelasticity and ultra-low impurities.
  • Cross-linked hyaluronic acid at 24 mg/ml combined with free HA fraction to balance structural support and deep hydration.
  • Incorporates 0.3% lidocaine for pain reduction during injection.
  • Designed for injection into the mid to deep dermis depending on indication and treatment area.
  • High Density Tapping / Ultra High Density technology and advanced physical cross-linking to achieve smooth extrusion and even tissue integration.
  • CE-marked dermal filler produced under strict quality control, including EDQM-approved HA raw material and extensive purification steps.

Packaging

  • Box containing 1 x 1 ml pre-filled, sterile, single-use glass syringe of Nexfill Deep (with Lidocaine).
  • Typically supplied with 2 x sterile disposable needles (commonly 27G 1/2" or 30G 1/2" as specified on the pack) suitable for mid to deep dermal injection.
  • Syringe and needles packed in a sterile blister with tamper-evident packaging.
  • Outer carton labelled with product name (NEXFILL Deep), volume (1 ml), composition (24 mg/ml HA with 0.3% lidocaine), lot number, expiry date, storage conditions, CE mark and manufacturer details (Nexus Pharma).

Usage

  • For professional use only: Nexfill Deep should be administered exclusively by appropriately trained and licensed healthcare professionals experienced in injectable dermal fillers.
  • Before treatment, take a full medical history, assess indications (e.g., deep wrinkles, lips, nasolabial folds, marionette lines, nose/forehead contour, chin augmentation) and rule out contraindications; obtain informed consent.
  • Cleanse and disinfect the treatment area thoroughly using an appropriate antiseptic solution.
  • Attach a sterile needle (as recommended in the instructions for use) to the pre-filled syringe using the Luer lock connection; ensure the needle is secure and remove any air bubbles carefully.
  • Injection depth is typically mid to deep dermis depending on the specific area: deeper for pronounced folds and structural contouring, more superficial within the mid-dermis for wrinkle filling.
  • Use appropriate injection techniques (e.g., linear threading, serial puncture, fanning or cross-hatching) and inject slowly, applying minimal pressure and small aliquots to avoid overcorrection.
  • Gently mould and massage the area after injection if required to ensure even distribution and smooth contours, avoiding excessive pressure that might displace the product.
  • Do not overcorrect; remember that slight swelling immediately after treatment may temporarily exaggerate the effect.
  • Advise patients to avoid touching or massaging the treated areas unnecessarily, to refrain from intense exercise, alcohol consumption, extreme heat or cold exposure (sauna, sunbeds) for at least 24 hours, and to follow any additional post-care guidance.
  • If needed, a touch-up session may be scheduled after the initial swelling resolves, usually within a few weeks, to fine-tune results.
  • Do not inject into blood vessels; always inject slowly and with awareness of vascular anatomy. In case of suspected vascular compromise, follow local emergency protocols and product/clinical guidelines.
  • Never mix Nexfill Deep with other products in the same syringe and never reuse leftover product or opened syringes.

Contraindications

  • Hypersensitivity or allergy to hyaluronic acid, lidocaine, other amide-type local anaesthetics or any of the excipients.
  • History of severe allergic reactions or anaphylaxis.
  • Presence of active skin infection, inflammation, herpes or other dermatologic conditions at or near the intended injection site.
  • Autoimmune diseases, immunosuppression or uncontrolled systemic illnesses where dermal filler injections may pose additional risk, unless carefully evaluated and accepted by the treating physician.
  • Known bleeding disorders or current significant anticoagulant/antiplatelet therapy that may increase the risk of bruising or haematoma, unless managed according to medical judgement.
  • Pregnancy and breastfeeding, due to insufficient safety data in these populations.
  • History of keloid or hypertrophic scarring, or known granulomatous disorders, where dermal fillers may carry a higher risk of adverse tissue reactions.
  • Previous permanent or semi-permanent fillers in the planned treatment area, which may increase complication risk, unless thoroughly assessed by an experienced injector.
  • Any other contraindications listed in the official Nexfill Deep instructions for use or applicable clinical guidelines.

Adverse Effects

  • Common, usually transient injection-site reactions such as redness (erythema), swelling, tenderness, pain, warmth, itching or mild bruising.
  • Temporary lumps, bumps or irregularities at the injection site, which generally resolve as the product integrates or can be gently massaged if appropriate.
  • Local haematoma or ecchymosis due to needle puncture of small vessels.
  • Short-lived numbness or altered sensation related to lidocaine and injection trauma.
  • Less common inflammatory reactions such as prolonged redness, oedema or induration, which may require clinical assessment and management.
  • Rare hypersensitivity reactions, nodules, granulomas or delayed inflammatory responses that may require medical treatment (e.g., anti-inflammatory medications, hyaluronidase, or other interventions).
  • Very rare but serious complications associated with dermal filler injections, including intravascular injection leading to vascular occlusion, skin necrosis, visual disturbance or blindness; these require immediate recognition and emergency management according to established protocols.
  • Any persistent, unusual or severe adverse event should be documented, closely monitored and managed by a qualified healthcare professional, with reporting through relevant pharmacovigilance or device vigilance systems.

Storage Conditions

  • Store between 2°C and 25°C as specified by the manufacturer; do not freeze.
  • Protect from direct sunlight and excessive heat; keep in the original blister and outer carton until use.
  • Do not use the product after the expiry date printed on the packaging.
  • Do not use if the blister pack, syringe or packaging is damaged or if the sterility of the product is in doubt.
  • Store out of reach of children and unauthorised persons; for professional use only.

Duration

Clinical and manufacturer information indicate that results with Nexfill Deep generally last around 6\u201312 months, depending on the treatment area, injection technique, the amount of product used, and individual factors such as age, skin type, metabolism and lifestyle. Some structural indications may show persistence toward the upper end of this range, with maintenance treatments scheduled as required.

Onset

A visible improvement in volume, contour and wrinkle reduction is typically immediate after injection, although final results are usually assessed after initial swelling and redness subside over several days to a couple of weeks. Hydration and skin-quality benefits may continue to develop over the following weeks as the gel integrates and stimulates fibroblast activity.

Browse more Dermal filler

Top Treatments

Top Cities in the UK